<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954081</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-PSOR-024</org_study_id>
    <nct_id>NCT02954081</nct_id>
  </id_info>
  <brief_title>APremilast After FumaRic Acid Ester Treatment</brief_title>
  <acronym>APART</acronym>
  <official_title>Real-world Benefit of Apremilast Treatment of Patients With Moderate-to-severe Psoriasis After Transition From Fumaric Acid Esters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient treatment preference and treatment satisfaction of physicians and patients comparing
      fumaric acid ester therapy with subsequent apremilast treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2017</start_date>
  <completion_date type="Anticipated">May 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean absolute value of the overall TSQM score at week 24 of apremilast (APR) therapy (phase II).</measure>
    <time_frame>56 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase I: Fumaric acid esters. Phase II: Apremilast</intervention_name>
    <description>Apremilast</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Adult patients ≥18 years

          -  Moderate to severe plaque-type psoriasis according to SmPC
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients ≥18 years

          -  Moderate to severe plaque-type psoriasis according to SmPC

          -  Phase I: Patients will be included once they are started on systemic fumaric acid
             esters (e.g. Fumaderm initial®) for the treatment of moderate-to-severe psoriasis
             vulgaris. Patients initiated on fumaric acid esters will be followed for a maximum of
             24 weeks during phase I. Patients continued on fumaric acid esters beyond 24 weeks or
             switched to a therapy other than apremilast during or at the end of the 24-week phase
             I period will no longer be followed.

          -  Phase II: Patients switched to apremilast during or at the end of the 24-week phase I
             period will be included in phase II and followed for additional 32 weeks.

          -  Written informed consent

        Exclusion Criteria:

          -  Prior treatment with biologics

          -  According to SmPC

          -  Participation in another clinical trial (parallel inclusion in the National psoriasis
             registry PsoBest is allowed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT02954081?term=CC-10004-PSOR-024&amp;rank=1</url>
    <description>Expanded Access for CC-10004</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

